On August 4, it was reported that Hanyu Pharmaceutical (300199.SZ) lifted its daily limit in the afternoon, offering a price of 24.32 yuan, and its share price hit a new high since December 2022. On the news front, Hanyu Pharmaceutical and digital asset platform KuCoin officially signed a letter of intent for strategic cooperation. The two parties plan to jointly explore in Hong Kong to jointly promote the first RWA(Real World Asset) tokenization pilot project in mainland China with "future income rights from innovative drug research and development" as the underlying asset. According to the agreement, Hanyu Pharmaceutical will use its technical accumulation and R & D pipeline in the field of GLP-1 polypeptide heavyweight drugs as its basic assets, while KuCoin will leverage its expertise in blockchain technology, RWA full-process solutions and global compliance. The advantages in terms of resources provide integrated support for the project such as on-chain mapping, asset tokenization, transaction matching, and revenue distribution. (Gelonghui)